This program will address the burden of hyperkalemia on RAAS inhibitor therapy, examining its impact on patient management. It will review the latest Chronic Kidney Disease (CKD) and Heart Failure (HF) guidelines for hyperkalemia management. Additionally, the program will provide an overview of Lokelma's product information, along with clinical trial data and real-world evidence, particularly focusing on its use in patients receiving RAAS inhibitors. This comprehensive discussion aims to enhance understanding and optimize approaches to managing hyperkalemia in clinical practice.
